Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (NASDAQ: QTRX) generates news that spans scientific breakthroughs, clinical research, corporate developments, and financial performance, all centered on its ultra-sensitive Simoa biomarker detection technology and spatial biology capabilities. As a life sciences company active in testing laboratories and professional scientific services, Quanterix regularly reports on studies, collaborations, and product launches that affect disease research and diagnostics.
Investors and researchers following QTRX news will see coverage of peer‑reviewed studies that rely on Simoa assays, such as large population-based analyses of Alzheimer’s Disease Neuropathological Changes using p‑Tau 217, and multiple sclerosis research that combines GFAP and NfL biomarkers for personalized monitoring. These articles illustrate how Quanterix assays and reference databases are applied in real-world clinical and epidemiological settings.
The company also issues updates on new assay launches and platform enhancements, including commercial introductions of p‑Tau 205 and p‑Tau 212 assays for Alzheimer’s research, and developments at the Quanterix Accelerator Laboratory, which supports clinical testing and global clinical trials. News items may highlight regulatory milestones, such as clinical laboratory permits and medical device registrations for specific assay kits in various markets.
From a corporate and capital markets perspective, Quanterix news includes quarterly financial results, non‑GAAP performance metrics, and commentary on integration progress following its acquisition of Akoya Biosciences. Filings and press releases discuss cost synergies, revenue composition across product and service lines, and governance changes such as cooperation agreements with shareholders and Board structure updates.
This QTRX news page brings together these updates so readers can track scientific publications, diagnostic advancements, spatial biology integration, and financial disclosures in one place.
Quanterix Corporation (NASDAQ: QTRX) will release its Q1 2022 financial results on May 10, 2022, before trading begins. The management team, including President & CEO Masoud Toloue and CFO Michael Doyle, will discuss the results in a conference call at 8:30 a.m. EST. Interested listeners can join the call via phone or a live webcast. Quanterix specializes in digitizing biomarker analysis to enhance precision health through its Simoa technology, supporting research across various therapeutic areas.
Quanterix Corporation (NASDAQ: QTRX) announced that its Simoa® neurofilament light chain (NfL) plasma test received FDA Breakthrough Device designation for assessing disease activity in relapsing-remitting multiple sclerosis (RRMS) patients. This designation supports accelerated development and regulatory review for technologies that address significant medical needs. The NfL test quantitatively measures NfL in blood, aiding in identifying RRMS patients' relapse risks. This marks the second Breakthrough Device designation for Quanterix, following the phospho-Tau 181 test for Alzheimer’s disease.
Quanterix Corporation (NASDAQ: QTRX) has announced a significant advancement in multiple sclerosis (MS) management through its Simoa® technology. A comprehensive study published in The Lancet Neurology established reference ranges for the serum neurofilament light chain (sNfL) biomarker, aiding in disease assessment at the individual level. The study analyzed over 20,000 samples, creating a robust database for clinical interpretation. This development hopes to enhance personalized treatment decisions for MS patients.
Quanterix Corporation (NASDAQ: QTRX) has partnered with the Alzheimer’s Drug Discovery Foundation (ADDF) to enhance the development of a multi-analyte plasma test for early Alzheimer's disease detection. Funded clinical trials will be conducted in collaboration with Amsterdam University Medical Centers, led by Professor Charlotte Teunissen. The initiative aims to provide accessible diagnostics to link patients with new therapies. The ADDF has financed over $209 million for Alzheimer's drug development since its inception.
Quanterix Corporation (NASDAQ: QTRX) will have its Chairman and CEO, Kevin Hrusovsky, present at the Barclays Global Healthcare Conference on March 15, 2022, at 10:45 a.m. EST. Attendees can register for virtual participation. Hrusovsky will also conduct one-on-one meetings with institutional investors on the same day. A live webcast of his presentation will be available on the Quanterix investor relations website, with replays accessible for 90 days. Quanterix specializes in digitizing biomarker analysis to enhance precision health.
Quanterix Corporation (NASDAQ: QTRX) has announced that its Chairman and CEO, Kevin Hrusovsky, will present at The Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:50 a.m. EST. Investors can register for a live webcast at the Quanterix investor relations page. Additionally, Hrusovsky will hold virtual meetings with institutional investors on March 8 and 9. Quanterix aims to advance precision health through its Simoa technology to enable early disease detection and better treatment methods.
Quanterix Corporation has entered a collaboration with Eli Lilly to enhance the diagnosis and treatment of Alzheimer’s disease. This partnership includes a non-exclusive license to Lilly’s P-tau217 antibody technology and a commitment of $11 million from Lilly for development this year. The collaboration aims to develop blood-based biomarkers, which could simplify and improve Alzheimer’s diagnostics and treatment monitoring, potentially reducing reliance on invasive procedures. The initiative puts Quanterix in a strong position in Alzheimer’s research and diagnostics.
Quanterix Corporation (NASDAQ: QTRX) announced a leadership transition effective April 25, 2022.
Quanterix Corporation (NASDAQ: QTRX) reported a strong financial performance for the fourth quarter and full year of 2021, achieving a 28% increase in GAAP total revenue, reaching $110.6 million. Notable highlights include a 49% rise in product revenue for Q4, totaling $23.5 million. The company ended the year with approximately $399 million in cash. Key advancements included FDA Breakthrough Device Designation for the pTau-181 blood test for Alzheimer’s disease and successful collaboration agreements with Eli Lilly. A leadership transition is set for April 2022, with Masoud Toloue becoming CEO.
Quanterix Corporation (NASDAQ: QTRX) has received multiple awards in the 2021 Best Places to Work Awards by Comparably, highlighting its commitment to a diverse and inclusive workplace. The company was recognized in five categories: Best Company for Diversity, Best Company for Women, Best Company Culture, Best Company Happiness, and Best Company Compensation. The awards were based on over 1,000 employee ratings. CEO Kevin Hrusovsky emphasized the importance of fostering an environment where all employees feel valued and empowered.